This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The use of extracorporeal membrane oxygenation in the management of ARDS has grown considerably in the past decade, largely as a consequence of improvements in extracorporeal technology and management techniques. Recently published data has helped clarify the use of ECMO in ARDS, and its role in optimizing lung-protective ventilation and minimizing ventilator-induced lung injury has the potential to have a substantial impact on ARDS management and outcomes. In the future, novel extracorporeal management strategies may lead to a new paradigm in our approach to patients with ARDS.
Footnotes
- Correspondence: Natalie Yip MD, Division of Pulmonary, Allergy & Critical Care, Department of Medicine, 622 W 168th Street, PH 8-101E, New York, NY 10032. E-mail: nhy1{at}cumc.columbia.edu.
Dr Brodie discloses relationships with ALung Technologies and Johnson & Johnson. The remaining authors have disclosed no conflicts of interest.
- Copyright © 2018 by Daedalus Enterprises
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$15.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Log in using your username and password
